Description

In this ERN Rare-Liver webinar, held on 20 December 2022, the panel discussed how to screen for biliary atresia, future paradigms for treating biliary atresia and the role of the EBAR registry.

Targeted Audience

  • General practitioners
  • Hepatologists
  • Oncologists
  • Health care professionals

 

Chair

Ekkehard Sturm Ekkehard Sturm is currently leading the Pediatric Gastroenterology/ Hepatology group, University of Tuebingen, Children´s Hospital. This tertiary care facility is one of the largest national programs for pediatric liver transplantation. Research interests include Rare Liver Diseases and Liver Transplantation and Immunomodulation. His research interests are focussed on pathophysiology of cholestastic liver diseases, novel therapies including modifiers of the enterohepatic circulation and mesenchymal stroma cells for immmune-modulatory purposes. He was co-coordinator of the European Reference Network Rare Liver 2017-2021 and is leading the center for rare liver diseases at UK Tübingen.

Speakers 

Omid Madadi-Sanjani Omid Madadi-Sanjani is a board certified general surgeon and pediatric surgeon, with special interest in pediatric hepatobiliary surgery. He is the current lead of the pediatirc surgical BA working group at the Hannover Medical School and is the PI of a regional screening program for BA in Lower Saxony. Furthermore, he is part of the expert consultant group of the Federal Joint Committee for the screening of BA in Germany.
Orith Waisbourd-Zinman Orith Waisbourd-Zinman is an assistant professor of Pediatrics at Tel-Aviv University and is a pediatric gastroenterologist at Schneider Children’s Medical Center of Israel. Dr. Waisbourd has completed her GI training at the Children’s Hospital of Philadelphia and a post-doctoral fellow-ship at the University of Pennsylvania. Dr. Waisbourd’s research group studies mechanisms of cholangiocyte injury and recovery in biliary atresia and other cholangiopathies using human or-ganoids model as well as mice models.